EcoDrugPlus

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSSTUG00000022540
Gene Symbol: LOC115180074
3 Cross references
190 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5-Like

Ensembl ID : ENSSTUG00000030113
Gene Symbol: LOC115162729
3 Cross references
188 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5-Like

Ensembl ID : ENSSTUG00000048031
Gene Symbol: LOC115174380
3 Cross references
184 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5-Like

Ensembl ID : ENSSTUG00000030455
Gene Symbol: LOC115172648
3 Cross references
189 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5-Like

Ensembl ID : ENSSTUG00000014777
Gene Symbol: LOC115156779
3 Cross references
183 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSSTUG00000038486
Gene Symbol: NPR2
3 Cross references
185 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSSTUG00000015211
Gene Symbol: LOC115199403
3 Cross references
197 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSSTUG00000012059
Gene Symbol: LOC115199909
3 Cross references
194 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSSTUG00000035570
Gene Symbol: LOC115159080
3 Cross references
196 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSSTUG00000039930
Gene Symbol: LOC115164727
3 Cross references
192 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2-Like

Ensembl ID : ENSSTUG00000017994
Gene Symbol: LOC115171254
3 Cross references
197 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSSTUG00000048775
Gene Symbol: LOC115201638
3 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).